Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMT-111 in Terminal Stage Solid Tumors
NCT04520386Phase 2Unknown
- Sponsor
- MetiMedi Pharmaceuticals
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of OMT-111 in non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), pancreatic adenocarcinoma (PDAC), sponsored by MetiMedi Pharmaceuticals. Status: unknown.
02
Drugs
OMT-111
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04520386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520386.